SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
NEW YORK, Jan. 22, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Vital Therapies, Inc. (NASDAQ: VTL) securities from April 17, 2014 through August 21, 2015 all dates inclusive (the “Class Period”) of the February 1, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Vital Therapies investors under the federal securities laws.
To join the Vital Therapies class action, go to the website at http://www.rosenlegal.com/cases-671.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose material information regarding Vital Therapies’ ELAD System studies, VTI-208, VTI-210, and VTI-212, including: (1) the studies’ independent significance; (2) the degree to which the studies were interrelated; and (3) that in the case of the failure of the VTI-208 trial, Vital Therapies would not continue the VTI-210 trial. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-671.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] www.rosenlegal.com
